tradingkey.logo

Opus Genetics Inc <IRD.OQ> expected to post a loss of 5 cents a share - Earnings Preview

ReutersMar 4, 2025 1:48 PM
  • Opus Genetics Inc IRD.OQ IRD.O is expected to show a rise in quarterly revenue when it reports results on March 6 (estimated) for the period ending December 31 2024

  • The Durham North Carolina-based company is expected to report a 425.0% increase in revenue to $8.879 million from $1.69 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Opus Genetics Inc is for a loss of 5 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Opus Genetics Inc is $9.50​, above​ its last closing price of $0.97. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.25

-0.24

-0.29

Missed

-22.1

Jun. 30 2024

-0.28

-0.25

-0.30

Missed

-17.6

Mar. 31 2024

-0.11

-0.13

-0.29

Missed

-116.4​

Dec. 31 2023

-0.03

-0.05

-0.21

Missed

-300

​​Sep. 30 2023

-0.24

-0.22

0.25

Beat

212.6

Jun. 30 2023

-0.25

-0.23

-0.24

Missed

-6.2​

Mar. 31 2023

-0.18

-0.15

-0.28

Missed

-81.8

Dec. 31 2022

0.97

1.58

Beat

63.3

This summary was machine generated March 4 at 13:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI